Shopping Cart

Your shopping cart is currently empty

Valpromide

Name: Valpromide
Brand: TargetMol
SKU: T0355
Price: 30 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T0355Cas No. 2430-27-5

Alias Valpramide, Dipropylacetamide, Depamide, 2-propylpentanamide

Valpromide (Dipropylacetamide) is a carboxamide derivative of valproic acid, used in the treatment of epilepsy and some affective disorders.

Valpromide

Copy Product Info

😃Good

Purity: 99.72%

Catalog No. T0355Alias Valpramide, Dipropylacetamide, Depamide, 2-propylpentanamideCas No. 2430-27-5

Valpromide (Dipropylacetamide) is a carboxamide derivative of valproic acid, used in the treatment of epilepsy and some affective disorders.

Pack Size	Price	USA Warehouse	Global Warehouse
50 mg	$30	In Stock	In Stock
100 mg	$44	In Stock	In Stock
500 mg	$98	In Stock	In Stock
1 g	$148	-	In Stock
1 mL x 10 mM (in DMSO)	$30	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.72%

Appearance:Solid

Color:White

Resource Download

COA HNMR LCMS

Product Introduction

Valpromide AI Summary

Valpromide exhibits a diverse range of bioactivities across multiple biological targets and assays. In anticonvulsant models, COMPOUND 150721 demonstrated effectiveness against maximal electroshock seizures in mice, with an ED50 of 14.9 mg/kg after 30 minutes of intraperitoneal administration and 11.4 mg/kg after 3 hours. The substance also showed protective effects against seizures induced by scMet and displayed antiepileptic activity in CF1 mice (ED50 of 32.0 mg/kg), with minimal motor impairment at higher doses, indicating a good safety margin. Additionally, the compound exhibits antiallodynic activity in a rat model of spinal nerve ligation-induced neuropathic pain with an ED50 of 61.0 mg/kg. Valpromide inhibited Glycogen synthase kinase-3 alpha by 80.0% and Glycogen synthase kinase-3 beta by 35.5%. It also demonstrated 50.9% inhibition of microsomal epoxide hydrolase in human liver microsomes when tested with styrene oxide. In antiviral assays, Valpromide showed varying degrees of inhibition against SARS-CoV-2. Specifically, it inhibited cytotoxicity in Caco-2 and VERO-6 cells, with inhibition rates of 0.27% and 0.05% at 10 µM concentration after 48 hours, respectively. The compound also had a bioactivity of inhibiting SARS-CoV-2 3CL-Pro protease at a rate of 9.975% at 20 µM. Furthermore, Valpromide showed an inhibitory action on human HDAC6 enzyme, demonstrating 0.83% inhibition with a commercial peptide substrate and 48.98% with a custom peptide substrate. It also displayed binding affinity towards various human and rat receptors and ion channels, with AC50 values greater than 10,000 nM, and exhibited activity as both an antagonist and agonist at receptors such as human CHRM2, HTR1A, ADRA1A, ADRA2A, HTR2A, HTR2B, and CNR1. Lastly, Valpromide has a solubility of 3700.0 µg/mL in water, indicating good aqueous solubility, which is beneficial for its pharmacokinetic properties..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Valpromide (Dipropylacetamide) is a carboxamide derivative of valproic acid, used in the treatment of epilepsy and some affective disorders.
Synonyms	Valpramide, Dipropylacetamide, Depamide, 2-propylpentanamide

Chemical Properties

Molecular Weight	143.23
Formula	C₈H₁₇NO
Cas No.	2430-27-5
Smiles	C(CCC)(CCC)C(N)=O
Relative Density.	0.9636 g/cm3 (Estimated)

Storage & Solubility Information

Storage

store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 50 mg/mL (349.09 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (13.96 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	6.9818 mL	34.9089 mL	69.8178 mL	349.0889 mL
5 mM	1.3964 mL	6.9818 mL	13.9636 mL	69.8178 mL
10 mM	0.6982 mL	3.4909 mL	6.9818 mL	34.9089 mL
20 mM	0.3491 mL	1.7454 mL	3.4909 mL	17.4544 mL
50 mM	0.1396 mL	0.6982 mL	1.3964 mL	6.9818 mL
100 mM	0.0698 mL	0.3491 mL	0.6982 mL	3.4909 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc